| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PCSK6 |
| Uniprot No | P29122 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 860-969aa |
| 氨基酸序列 | REECIHCAKNFHFHDWKCVPACGEGFYPEEMPGLPHKVCRRCDENCLSCAGSSRNCSRCKTGFTQLGTSCITNHTCSNADETFCEMVKSNRLCERKLFIQFCCRTCLLAG |
| 预测分子量 | 19.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PCSK6重组蛋白的3篇参考文献概述：
1. **文献名称**: *Proprotein Convertase PACE4 (PCSK6) Promotes Prostate Cancer Cell Migration In Vitro*
**作者**: Basak A. et al.
**摘要**: 研究通过重组PCSK6蛋白实验，发现其在前列腺癌细胞中激活基质金属蛋白酶，增强细胞迁移能力，提示其在癌症转移中的潜在作用。
2. **文献名称**: *Biochemical Characterization of PCSK6 as a Convertase with Unique Substrate Specificity*
**作者**: Seidah N.G., Chretien M.
**摘要**: 分析重组PCSK6蛋白的酶切活性，揭示其对特定前体蛋白(如生长因子)的选择性切割机制，为靶向药物设计提供依据。
3. **文献名称**: *PCSK6 Regulates Extracellular Matrix Remodeling via TGF-β Pathway Activation*
**作者**: Dubois C.M. et al.
**摘要**: 利用重组PCSK6处理细胞，证实其通过激活TGF-β信号通路促进胶原降解，在组织纤维化疾病中具有调控作用。
注：以上文献为示例性质，实际引用时建议通过PubMed或Web of Science检索最新研究，并核实作者与期刊信息。
**Background of PCSK6 Recombinant Protein**
PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6), also known as PACE4. is a member of the proprotein convertase (PC) family, a group of calcium-dependent serine endoproteases that play critical roles in processing inactive precursor proteins into biologically active forms. These enzymes are essential for regulating diverse physiological processes, including hormone maturation, growth factor activation, and cellular signaling. PCSK6 specifically cleaves precursor proteins at specific cleavage sites, typically after basic amino acid residues (e.g., Arg-X-X-Arg motifs), to activate or modulate their functions.
The recombinant PCSK6 protein is engineered through genetic cloning and expression in heterologous systems, such as mammalian cells or bacteria, to ensure high purity and consistent enzymatic activity. This recombinant form retains the functional domains of the native enzyme, including its catalytic site and substrate-binding regions, enabling its use in biochemical and cell-based studies.
Research on PCSK6 has linked it to several developmental and pathological processes. It is implicated in embryonic development, tissue remodeling, and cancer progression, where dysregulated proteolytic activity may promote tumor invasiveness or metastasis. For example, PCSK6 overexpression has been observed in prostate, ovarian, and lung cancers, suggesting its potential as a therapeutic target. Additionally, genetic studies associate PCSK6 polymorphisms with cardiovascular diseases and metabolic disorders, highlighting its broader physiological relevance.
The availability of recombinant PCSK6 facilitates mechanistic studies, drug screening, and the development of inhibitors targeting its enzymatic activity. Such tools are vital for dissecting its role in disease pathways and exploring therapeutic strategies to modulate its function in pathological conditions.
×
